MENU
+Compare
BCRX
Stock ticker: NASDAQ
AS OF
Apr 3, 04:59 PM (EDT)
Price
$7.32
Change
-$0.11 (-1.48%)
Capitalization
1.55B

BCRX BioCryst Pharmaceuticals Forecast, Technical & Fundamental Analysis

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases... Show more

Industry: #Biotechnology
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for BCRX with price predictions
Apr 02, 2025

BCRX's RSI Oscillator ascending out of oversold territory

The RSI Indicator for BCRX moved out of oversold territory on March 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In of the 27 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BCRX advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

BCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 175 cases where BCRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on April 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at .

BCRX moved below its 50-day moving average on March 05, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BCRX crossed bearishly below the 50-day moving average on March 11, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (252.036).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

BCRX is expected to report earnings to fall 43.85% to -7 cents per share on May 01

BioCryst Pharmaceuticals BCRX Stock Earnings Reports
Q1'25
Est.
$-0.07
Q4'24
Missed
by $0.06
Q3'24
Est.
$-0.07
Q2'24
Beat
by $0.11
Q1'24
Beat
by $0.04
The last earnings report on February 24 showed earnings per share of -12 cents, missing the estimate of -7 cents. With 1.93M shares outstanding, the current market capitalization sits at 1.55B.
A.I. Advisor
published General Information

General Information

a developer of small molecule pharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4505 Emperor Boulevard
Phone
+1 919 859-1302
Employees
536
Web
https://www.biocryst.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SQCBX12.88N/A
N/A
X-Square Balanced Fund, LLC C
PURAX19.46N/A
N/A
PGIM Global Real Estate A
TWUAX76.67N/A
N/A
American Century Ultra® A
HICVX22.05N/A
N/A
Hennessy Cornerstone Value Inst
NMSCX20.93N/A
N/A
Columbia Small Cap Index Inst

BCRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+2.48%
VCYT - BCRX
46%
Loosely correlated
+1.93%
OCGN - BCRX
38%
Loosely correlated
+6.46%
ARWR - BCRX
37%
Loosely correlated
+3.97%
PRTA - BCRX
36%
Loosely correlated
+3.41%
DNLI - BCRX
36%
Loosely correlated
+11.80%
More

Groups containing BCRX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+2.48%
Pharmaceuticals
category (304 stocks)
6%
Poorly correlated
-1.15%